Routine pneumococcal vaccination of children provokes new patterns of serotypes causing invasive pneumococcal disease in adults and children

American Journal of the Medical Sciences

Volumn 345, Issue 2, 2013, Pages 112-120

  Norton, Nancy B ^a,b   Stanek, Ronald J ^a,b   Mufson, Maurice A ^a,b  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Invasive pneumococcal disease; PCV7 pneumococcal serotypes; Protein conjugate 7 valent polysaccharide vaccine (PCV7); Replacement pneumococcal serotypes; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE;

ADULT; ARTICLE; CHILD; COMPARATIVE STUDY; DISEASE SURVEILLANCE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PREVALENCE; RISK REDUCTION; SCHOOL CHILD; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINATION;

EID: 84873202344     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182517785     Document Type: Article

References (60)

1. Mufson MA. Pneumococcus. In: Schlossberg, D, editor. Clinical infectious disease. 3rd ed. New York (NY): Cambridge University Press; 2008. p. 1023-30
2. CDC. Active Bacterial Core Surveillance (ABCs) Report: Emerging Infections Program Network. Streptococcus pneumoniae, provisional- 2009. Atlanta (GA): US Department of Health and Human Services, CDC; 2010. Available at: Http://www.cdc.gov/abcs/reports-findings/- survreports/spneu09.pdf
3. Smit P, Oberholzer D, Hayden-Smith S, et al. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977;238:2613-6
4. Hilleman MR, McLean AA, Vella PP, et al. Polyvalent pneumococcal polysaccharide vaccines. Bull World Health Organ 1978;56:371-5
5. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010;59:1102-6
6. Spindler C, Hedlund J, Jasir A, et al. Effects of a large-scale introduction of the pneumococcal polysaccharide vaccine among elderly persons in Stockholm, Sweden. Vaccine 2008;26:5541-6
7. Christenson B, Hedlund J, Lundgergh P, et al. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004;23:363-8
8. Moberley SA, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008;1: CD000422
9. Shinefield HR, Black S. Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr Infect Dis J 2000;19:394-7
10. Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 2007;25:2194-212
11. Calbo E, Garau J. Invasive pneumococcal disease in children: Changing serotypes and clinical expression of disease. Clin Infect Dis 2005; 41:1821-3
12. Aguiar SI, Brito MJ, Marques JG, et al. Serotypes 1, 7F and 19A became the leading causes of pediatric invasive pneumococcal infections in Portugal after 7 years of heptavalent conjugate vaccine use. Vaccine 2010;28:5167-73
13. Beall B, McEllistrem MC, Gertz RE, et al. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 2006;44:999-1017
14. Byington CL, Samore MH, Stoddard GJ, et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: Emergence of nonvaccine serogroups. Clin Infect Dis 2005;41:21-9
15. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007;196:1346-54
16. Hsu KK, Shea KM, Stevenson AE, et al. Changing serotypes causing childhood invasive pneumococcal disease. Ped Infect Dis J 2010;29:289-93
17. Aguiar SI, Serrano I, Pinto FR, et al. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin Microbiol Infect 2008;14:835-43
18. Jacobs MR, Good CE, Bajaksouzian S, et al. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis 2008;47:1388-95
19. Jacobs MR, Good CE, Beall B, et al. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: A quarter century of experience. J Clin Microbiol 2008;46: 982-90
20. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. New Engl J Med 2006;354:1455-63
21. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005;294:2043-51
22. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006;295:1668-74
23. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native Children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007;297:1784-92
24. Weatherholz R, Millar EV, Moulton LH, et al. Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Clin Infect Dis 2010;50:1238-46
25. Steenhoff AP, Shah SS, Ratner AJ, et al. Emergence of vaccinerelated pneumococcal serotypes as a cause of bacteremia. Clin Infect Dis 2006;42:907-14
26. Hsu K, Pelton S, Karumuri S, et al. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J 2005;24:17-23
27. Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 2010;125:429-36
28. Mahjoub-Messai F, Doit C, Koeck JL, et al. Population snapshot of Streptococcus pneumoniae serotype 19A isolates before and after introduction of seven-valent pneumococcal vaccination for French children. J Clin Microbiol 2009;47:837-40
29. Munoz-Almagro C, Esteva C, Fernandez de Sevilla M, et al. Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona. J Infect 2009;59:75-82
30. Picazo J, Ruiz-Contreras J, Casado-Flores J, et al. Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar. Clin Vaccine Immunol 2011;18:89-94
31. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41
32. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Ped Infect Dis J 2007;26:468-72
33. Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009;49:1318-25
34. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: A 20-year longitudinal study, 1978-1997. Am J Med 1999;107:34S-43S.
35. Stanek RJ, Mufson MA. A 20-year epidemiological study of pneumococcal meningitis. Clin Infect Dis 1999;28:1265-72
36. Mufson MA, Chan G, Stanek RJ. Penicillin resistance not a factor in outcome from invasive Streptococcus pneumoniae community-acquired pneumonia in adults when appropriate empiric therapy started. Am J Med Sci 2007;333:161-7
37. Austrian R. The Quellung reaction, a neglected microbiologic technique. Mount Sinai J Med 1976;43:699-703
38. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing (CLSI Document M100-S16
39. Sixteenth Informational Supplement. Wayne (PA): Clinical and Laboratory Standards Institute; 2006
40. Black S, Shinefield H, Baxter R, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Ped Infect Dis J 2004;23:485-9
41. Park IH, Pritchard DG, Cartee R, et al. Discovery of a new capsular serotype (6C) within sero-group 6 of Streptococcus pneumoniae. J Clin Microbiol 2007;45:1225-33
42. Carvalho MG, Pimenta FC, Gertz RE Jr, et al. PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. J Clin Microbiol 2009;47:554-9
43. Park H, Moore MR, Treanor TR, et al. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 2008;198: 1818-22
44. Turner P, Hinds J, Turner C, et al. Improved detection of nasopharyngeal colonization by multiple pneumococcal serotypes by use of latex agglutination or molecular serotyping by microarray. J Clin Microbiol 2011;49:1784-9
45. Veenhoven RH, Bogaert D, Schilder AG, et al. Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media. Clin Infect Dis 2004;39:911-9
46. Melegaro A, Gay NJ, Medley GF. Estimating the transmission parameters of pneumococcal carriage in households. Epidemiol Infect 2004; 132:433-41
47. Nesin M, Ramirez M, Tomasz A. Capsular transformation of a multidrug- resistant serotype 23F Streptococcus pneumoniae in vivo. J Infect Dis 1998;177:707-13
48. Barnes DM, Whittier S, Gilligan PH, et al. Transmission of multidrug- resistant serotype 23F Streptococcus pneumoniae in group day care: Evidence suggesting capsular transformation of the resistant strain in vivo. J Infect Dis 1995;171:890-6
49. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 1984;101:325-30
50. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. New Engl J Med 1991;325:1453-60
51. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994;154:2666-77
52. Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23- valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998;351:399-403
53. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-46
54. Harfouche C, Filippini S, Gianfaldoni C, et al. RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies. Infect Immun 2012;80:451-60
55. Olafsdottir TA, Lingnau K, Nagy E, et al. Novel protein-based pneumocccal vaccines administered with the Th-1-promoting adjuvant IC31 induce protective immunity against pneumococcal disease in neonatal mice. Infect Immun 2012;80:461-8
56. Cron LE, Stol K, Burghout P, et al. Two DHH subfamily-1 proteins contribute to pneumococcal virulence and confer protection against pneumococcal disease. Infect Immun 2011;79:3697-710
57. Munoz-Almagro C, Jordan I, Gene A, et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008;46:174-82
58. Perez-Trallero E, Marimon JM, Ercibengoa M, et al. Invasive Streptococcus pneumonia infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine. Europ J Clin Microbiol Infect Dis 2009;28:731-8
59. Hennessy TW, Singleton RJ, Bulkow LR, et al. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: Progress towards elimination of a health disparity. Vaccine 2005;23:5464-73
60. Karnezis TT, Smith A,Whittier S, et al. Antimicrobial resistance among isolates causing invasive pneumococcal disease before and after licensure of heptavalent conjugate pneumococcal vaccine. PLoS Med 2009;4:1-5.